Papillary lung adenocarcinoma

Summary

Papillary lung adenocarcinoma (MONDO:0006049) is a disease. A subtype of papillary adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	papillary lung adenocarcinoma
Mondo ID	MONDO:0006049
EFO	EFO:1000046
DOID	DOID:5588
NCIT	C5650
SNOMED CT	707411007
UMLS	C1335325
MedGen	277495
GARD	0024275
Anatomy (UBERON)	UBERON:0002048
Is cancer (heuristic)	no

Also known as: lung papillary adenocarcinoma · lung papillary-adenocarcinoma · papillary adenocarcinoma of lung · papillary adenocarcinoma of the lung · papillary lung adenocarcinoma

Data availability: 11 cell lines.

Disease family

This is a subtype of papillary adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › papillary adenocarcinoma › papillary lung adenocarcinoma

Related subtypes (10): papillary eccrine carcinoma, breast papillary carcinoma, papillary thymic adenocarcinoma, fallopian tube papillary adenocarcinoma, ovarian serous surface papillary adenocarcinoma, gallbladder papillary neoplasm with an associated invasive carcinoma, papillary cystadenocarcinoma, thyroid gland papillary carcinoma, gastric papillary adenocarcinoma, papillary renal cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.